Ocular Therapeutix 2025 Investor Day September 30, 2025 Forward Looking Statements and Disclaimers Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development of, regulatory status of, and regulatory submissions regarding the Company's product candidates, including the timing, design, enrollment, randomization, and conduct of the Company's ongoing Phase 3 clinical trials and long-term extension study of AXPAXLI (also called OTX-TKI) for the ...